Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Avantax Advisory Services Inc. Has $10.10 Million Position in Bristol Myers Squibb Company $BMY
04:04am, Tuesday, 18'th Nov 2025
Avantax Advisory Services Inc. lessened its stake in Bristol Myers Squibb Company (NYSE: BMY) by 6.9% during the undefined quarter, according to the company in its most recent 13F filing with the SEC.
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
10:33pm, Monday, 17'th Nov 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers.
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
10:04am, Monday, 17'th Nov 2025
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
Why Are These 4 Dividend Stocks Still Trading At A Deep Discount?
07:46am, Monday, 17'th Nov 2025
Will the stock market finish the year higher or lower?
S&P 500 Gains and Losses Today: DoorDash Drives Higher on a New Partnership; Bristol-Myers Squibb Stock Falls
05:30pm, Friday, 14'th Nov 2025
Shares of a delivery giant surged Friday on a new partnership, while a pharmaceutical firm came under pressure after it halted a trial of a key heart treatment.
Major stock indexes were mixed Friday, with the Dow Jones Industrial Average declining for a second straight session but technology shares rebounding.
Stocks Paring Losses Even as Rate Cut Hopes Dwindle
12:11pm, Friday, 14'th Nov 2025
The Nasdaq and S&P 500 clawed their way into positive territory, but the Dow was set to extend losses
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy
11:17am, Friday, 14'th Nov 2025
Bristol Myers Squibb & Co. (NYSE: BMY), in collaboration with Johnson & Johnson (NYSE: JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safet
Bristol Myers, J&J halt heart drug trial after interim review
08:03am, Friday, 14'th Nov 2025
Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study
Update on Phase 3 Librexia ACS Trial
06:59am, Friday, 14'th Nov 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--Update on Phase 3 Librexia ACS Trial.
Bristol Myers Squibb Company $BMY Shares Sold by Arvest Bank Trust Division
04:45am, Friday, 14'th Nov 2025
Arvest Bank Trust Division lowered its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 65.3% in the second quarter, according to the company in its most recent 13F filing with the SE
Allianz SE Lowers Position in Bristol Myers Squibb Company $BMY
04:03am, Friday, 14'th Nov 2025
Allianz SE lessened its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exc
Advisors Capital Management LLC Has $40.37 Million Stake in Bristol Myers Squibb Company $BMY
03:13am, Friday, 14'th Nov 2025
Advisors Capital Management LLC boosted its position in Bristol Myers Squibb Company (NYSE: BMY) by 7.3% during the second quarter, according to its most recent disclosure with the Securities and Exch
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
02:45pm, Thursday, 13'th Nov 2025
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
10:41am, Thursday, 13'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
